Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

Haematologica. 2016 Mar;101(3):263-5. doi: 10.3324/haematol.2015.139246.

Affiliations

¹ Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
² Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
³ Department of Internal Medicine III, Ulm University, Germany.
⁴ Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
⁵ Institute of Hematology and Oncology, Department of Hematology, Hospital Clinic, University of Barcelona, Spain.
⁶ Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
⁷ Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.
⁸ Division of Experimental Oncology and Department of Onco-Hematology, Università Vita-Salute San Raffaele and IRCCS Instituto Scientifico San Raffaele, Milan, Italy [email protected].

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Agammaglobulinaemia Tyrosine Kinase
Alleles
Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor / genetics*
Biomarkers, Tumor / metabolism
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Class I Phosphatidylinositol 3-Kinases / antagonists & inhibitors
Class I Phosphatidylinositol 3-Kinases / genetics
Class I Phosphatidylinositol 3-Kinases / metabolism
Gene Expression
Gene Frequency
High-Throughput Nucleotide Sequencing
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis*
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Molecular Targeted Therapy
Piperidines
Prognosis
Protein-Tyrosine Kinases / antagonists & inhibitors
Protein-Tyrosine Kinases / genetics
Protein-Tyrosine Kinases / metabolism
Purines / therapeutic use
Pyrazoles / therapeutic use
Pyrimidines / therapeutic use
Quinazolinones / therapeutic use
Sulfonamides / therapeutic use
Tumor Suppressor Protein p53 / deficiency
Tumor Suppressor Protein p53 / genetics*

Substances

Antineoplastic Agents
Biomarkers, Tumor
Bridged Bicyclo Compounds, Heterocyclic
Piperidines
Purines
Pyrazoles
Pyrimidines
Quinazolinones
Sulfonamides
TP53 protein, human
Tumor Suppressor Protein p53
ibrutinib
Class I Phosphatidylinositol 3-Kinases
PIK3CD protein, human
Protein-Tyrosine Kinases
Agammaglobulinaemia Tyrosine Kinase
Adenine
venetoclax
idelalisib